Skip to main content
Year archive

Kamada Ltd. — 2023 filings

All 61 regulatory filings released by Kamada Ltd. (KMDA) in 2023, sourced directly from the official regulator.

61 Filings
2023 Period
2023 filings (61)
Filing Released Lang
Results of Annual General Meeting of Shareholders held on December 28, 2023
AGM Information
2023-12-28 English
Results of Annual General Meeting of Shareholders held on December 28, 2023
Report Publication Announcement
2023-12-28 English
Immediate Report about change of identifying details
Regulatory Filings
2023-12-26 English
amada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Regulatory Filings
2023-12-06 English
amada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
Regulatory Filings
2023-12-06 English
FORM 6-K- ANNUAL GENERAL MEETING OF SHAREHOLDERS on Thursday, December 28, 2023, at 4:00 p.m.
Proxy Solicitation & Information Statement
2023-11-14 English
FORM 6-K- ANNUAL GENERAL MEETING OF SHAREHOLDERS on Thursday, December 28, 2023, at 4:00 p.m.
Proxy Solicitation & Information Statement
2023-11-14 English
FORM 6-K- ANNUAL GENERAL MEETING OF SHAREHOLDERS on Thursday, December 28, 2023, at 4:00 p.m.
AGM Information
2023-11-14 English
ANNUAL GENERAL MEETING OF SHAREHOLDERS WILL BE HELD ON DECEMBER 28,2023
Proxy Solicitation & Information Statement
2023-11-13 English
ANNUAL GENERAL MEETING OF SHAREHOLDERS WILL BE HELD ON DECEMBER 28,2023
AGM Information
2023-11-13 English
Reports 2023 Third Quarter Financial Results
Interim / Quarterly Report 9M 2023
2023-11-13 English
Reports 2023 Third Quarter Financial Results
Report Publication Announcement
2023-11-13 English
The company's financial results for the Third quarter 2023 were published abroad
Regulatory Filings
2023-11-13 Hebrew (modern)
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Earnings Release 9M 2023
2023-11-08 English
Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
Report Publication Announcement
2023-11-08 English
Announces Recent Achievements with CYTOGAM
Regulatory Filings
2023-10-16 English
Announces Recent Achievements with CYTOGAM
Report Publication Announcement
2023-10-16 English
Kamada Provides Corporate Update on its Israel Operations
Regulatory Filings
2023-10-10 English
Kamada Provides Corporate Update on its Israel Operations
Report Publication Announcement
2023-10-10 English
Prospectus $50,000,000 Ordinary Shares Offered by the Company or Announcement
Capital/Financing Update
2023-09-11 English
Prospectus $50,000,000 Ordinary Shares Offered by the Company or Announcement
Report Publication Announcement
2023-09-11 English
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
Regulatory Filings
2023-08-30 English
Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
Capital/Financing Update
2023-08-30 English
Second Quarter and First Half 2023 Financial Results
Interim / Quarterly Report H1 2023
2023-08-16 English
Second Quarter and First Half 2023 Financial Results
Earnings Release Q2 2023
2023-08-16 English
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
Earnings Release H1 2023
2023-08-09 English
Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
Report Publication Announcement
2023-08-09 English
Immediate Report of Meeting to be held on August 29, 2023, proxy statement
Proxy Solicitation & Information Statement
2023-07-14 English
Immediate Report of Meeting to be held on August 29, 2023, proxy statement
Proxy Solicitation & Information Statement
2023-07-14 English
Immediate Report of Meeting to be held on August 29, 2023, proxy statement
AGM Information
2023-07-14 English
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON August 29, 2023, PROXY STATEMENT
Proxy Solicitation & Information Statement
2023-07-14 English
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON August 29, 2023, PROXY STATEMENT
AGM Information
2023-07-14 English
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
Regulatory Filings
2023-07-12 English
Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S.
Report Publication Announcement
2023-07-12 English
Share purchase agreememnt with FIMI Opportunity Funds -FORM 6K
Regulatory Filings
2023-05-25 English
Share purchase agreememnt with FIMI Opportunity Funds -FORM 6K
M&A Activity
2023-05-25 English
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
Interim / Quarterly Report Q1 2023
2023-05-24 English
Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance
Report Publication Announcement
2023-05-24 English
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary
Regulatory Filings
2023-05-24 English
Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary
Board/Management Information
2023-05-24 English
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Capital/Financing Update
2023-05-24 English
Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds
Capital/Financing Update
2023-05-24 English
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Earnings Release Q1 2023
2023-05-17 English
First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023
Report Publication Announcement
2023-05-17 English
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Regulatory Filings
2023-05-16 English
amada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland
Report Publication Announcement
2023-05-16 English
U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings
2023-05-03 English
U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings
2023-05-03 English
Kamada Issues 2023 CEO Letter to Shareholders; Financial Results presentation
Regulatory Filings
2023-03-15 English
Kamada Issues 2023 CEO Letter to Shareholders; Financial Results presentation
Report Publication Announcement
2023-03-15 English
Kamada Files Annual Report for the Year Ended December 31, 2022
Regulatory Filings
2023-03-15 English
Kamada Files Annual Report for the Year Ended December 31, 2022
Report Publication Announcement FY 2022
2023-03-15 English
FORM 20-F For the fiscal year ended December 31, 2022
Regulatory Filings
2023-03-15 Hebrew (modern)
FORM 20-F For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-03-15 English
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
Earnings Release FY 2022
2023-03-15 English
Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth
Report Publication Announcement
2023-03-15 English
The company's financial results for 2022 reported abroad
Regulatory Filings
2023-03-15 Hebrew (modern)
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
Report Publication Announcement
2023-03-09 English
Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023
Report Publication Announcement
2023-03-09 English
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings
2023-01-04 English
Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel
Regulatory Filings
2023-01-04 English